These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7926260)

  • 61. Androgen receptor-mediated non-genomic effects of vinclozolin on porcine ovarian follicles and isolated granulosa cells: Vinclozolin and non-genomic effects in porcine ovarian follicles.
    Wartalski K; Knet-Seweryn M; Hoja-Lukowicz D; Tabarowski Z; Duda M
    Acta Histochem; 2016 May; 118(4):377-86. PubMed ID: 27094116
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.
    Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S
    Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
    Lippman M; Bolan G; Huff K
    Cancer Res; 1976 Dec; 36(12):4610-8. PubMed ID: 1000506
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiandrogen oligonucleotides: active principles in hair- and skin-derived culture cells.
    Balañá ME; Alvarez Roger C; Dugour AV; Kerner NA
    J Drugs Dermatol; 2004; 3(3):287-94. PubMed ID: 15176163
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
    Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens.
    Wakeling AE; Furr BJ; Glen AT; Hughes LR
    J Steroid Biochem; 1981 Dec; 15():355-9. PubMed ID: 7339263
    [No Abstract]   [Full Text] [Related]  

  • 67. Effect of antiandrogen treatment on chemical hepatocarcinogenesis in rats.
    Matsuura B; Taniguchi Y; Ohta Y
    J Hepatol; 1994 Aug; 21(2):187-93. PubMed ID: 7527437
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synthesis and structure-activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands.
    Van Dort ME; Jung YW
    Bioorg Med Chem Lett; 2001 Apr; 11(8):1045-7. PubMed ID: 11327585
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antiandrogens as environmental endocrine disruptors.
    Kelce WR; Gray LE; Wilson EM
    Reprod Fertil Dev; 1998; 10(1):105-11. PubMed ID: 9727600
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The androgen receptor: an overview.
    Zhou ZX; Wong CI; Sar M; Wilson EM
    Recent Prog Horm Res; 1994; 49():249-74. PubMed ID: 8146426
    [No Abstract]   [Full Text] [Related]  

  • 71. Nonsteroidal androgen receptor ligands: versatile syntheses and biological data.
    Varchi G; Guerrini A; Tesei A; Brigliadori G; Bertucci C; Di Donato M; Castoria G
    ACS Med Chem Lett; 2012 Jun; 3(6):454-8. PubMed ID: 24900495
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NRG1 can promote antiandrogen resistance.
    Kelsey R
    Nat Rev Urol; 2020 Sep; 17(9):486. PubMed ID: 32782364
    [No Abstract]   [Full Text] [Related]  

  • 73. Corrigendum: Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.
    Tian X; He Y; Zhou J
    Front Pharmacol; 2015; 6():97. PubMed ID: 26005418
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.
    Narayanan R
    Asian J Urol; 2020 Jul; 7(3):271-283. PubMed ID: 32742927
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Androgen receptor: structure, role in prostate cancer and drug discovery.
    Tan MH; Li J; Xu HE; Melcher K; Yong EL
    Acta Pharmacol Sin; 2015 Jan; 36(1):3-23. PubMed ID: 24909511
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress.
    Whitaker HC; Patel D; Howat WJ; Warren AY; Kay JD; Sangan T; Marioni JC; Mitchell J; Aldridge S; Luxton HJ; Massie C; Lynch AG; Neal DE
    Br J Cancer; 2013 Aug; 109(4):983-93. PubMed ID: 23880827
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain.
    Jasuja R; Ulloor J; Yengo CM; Choong K; Istomin AY; Livesay DR; Jacobs DJ; Swerdloff RS; Miksovská J; Larsen RW; Bhasin S
    Mol Endocrinol; 2009 Aug; 23(8):1231-41. PubMed ID: 19443608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch.
    Becker M; Martin E; Schneikert J; Krug HF; Cato AC
    J Cell Biol; 2000 Apr; 149(2):255-62. PubMed ID: 10769019
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Monoclonal anti-androgen receptor antibodies: production, characterization and potential diagnostic applications.
    Shih CC; Young WJ; Wang CH; Jin LP; Ji XD; Guan Q; Wang M; Chang C
    Mol Cell Biochem; 1999 Nov; 201(1-2):131-40. PubMed ID: 10630632
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
    Miyamoto H; Yeh S; Wilding G; Chang C
    Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.